INT79597

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.50
First Reported 1998
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 5
Total Number 5
Disease Relevance 3.39
Pain Relevance 0.41

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cytosol (PDE5A) signal transduction (PDE5A) cellular_component (PDE5A)
Anatomy Link Frequency
corpus 2
PDE5A (Homo sapiens)
Pain Link Frequency Relevance Heat
antagonist 15 100.00 Very High Very High Very High
addiction 1 96.04 Very High Very High Very High
drug abuse 1 95.48 Very High Very High Very High
cINOD 1 87.48 High High
adenocard 1 87.24 High High
Calcium channel 1 80.08 Quite High
Bioavailability 2 76.48 Quite High
Inflammation 1 63.12 Quite High
Arthritis 1 54.24 Quite High
fibrosis 1 36.48 Quite Low
Disease Link Frequency Relevance Heat
Pulmonary Hypertension 90 100.00 Very High Very High Very High
Heart Rate Under Development 2 99.60 Very High Very High Very High
Pressure And Volume Under Development 8 97.56 Very High Very High Very High
Reprotox - General 2 10 95.68 Very High Very High Very High
Arrhythmias 2 Under Development 2 95.64 Very High Very High Very High
Drug Dependence 1 95.48 Very High Very High Very High
Heart Disease 4 94.32 High High
Cancer 7 94.20 High High
Dyspnea 9 94.04 High High
Apoptosis 7 93.84 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
When sexual stimulation causes local release of NO, inhibition of PDE5 by sildenafil increases concentrations of cGMP in the corpus cavernosum, causing smooth muscle relaxation and blood flow into the penis, resulting in an erection.
Positive_regulation (increases) of Negative_regulation (inhibition) of PDE5 in corpus
1) Confidence 0.50 Published 1998 Journal Clin Ther Section Abstract Doc Link 9916601 Disease Relevance 0.15 Pain Relevance 0.04
This remains to be further evaluated since phosphodiesterase-5 inhibitors were also successfully used to treat pulmonary oedema.15
Positive_regulation (used) of Negative_regulation (inhibitors) of phosphodiesterase-5 associated with heart rate under development
2) Confidence 0.49 Published 2010 Journal Annals of the Rheumatic Diseases Section Body Doc Link PMC2938897 Disease Relevance 1.11 Pain Relevance 0.03
Patients were excluded if they were currently taking drugs that inhibit or induce hepatic cytochrome P450 3A4, nitrates, alpha blockers, or PDE5 inhibitors.
Positive_regulation (induce) of Negative_regulation (inhibitors) of PDE5
3) Confidence 0.42 Published 2008 Journal Psychopharmacology (Berl) Section Body Doc Link PMC2704618 Disease Relevance 0.92 Pain Relevance 0.10
Cell biological studies provided circumstantial evidence that the mechanism by which these agents exert their antitumor effect should be attributed to inhibition of cyclic-GMP phosphodiesterase (cGMP-PDE).
Positive_regulation (attributed) of Negative_regulation (inhibition) of cyclic-GMP phosphodiesterase
4) Confidence 0.25 Published 2001 Journal Curr Opin Investig Drugs Section Abstract Doc Link 11569947 Disease Relevance 0.57 Pain Relevance 0.09
Two classes of oral agents are recommended for the treatment of mild to moderate PAH (WHO functional class II/III).9,10 These include the endothelin receptor antagonists, bosentan, ambrisentan, and sitaxsentan, and the phosphodiesterase-5 inhibitors, sildenafil and tadalafil.
Positive_regulation (recommended) of Negative_regulation (inhibitors) of phosphodiesterase-5 associated with pulmonary hypertension and antagonist
5) Confidence 0.08 Published 2010 Journal Vascular Health and Risk Management Section Body Doc Link PMC3004515 Disease Relevance 0.64 Pain Relevance 0.17

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox